The novel ,S-lactam, L-640,876, exhibited excellent therapeutic activity when administered parenterally but not orally to mice infected with a variety of pathogenic bacteria. In this respect, the compound was as potent as cefotaxime against representative Gram-positive and Gram-negative organisms, in most cases, equal to or more potent than cefoxitin, and more effective than mecillinam. When administered subcutaneously to normal mice at dose levels ranging from 10 to 50 mg/kg, L-640,876 provided an adequate dose response, recovery of ca. 45% of biological activity in the urine, and excellent distribution at the highest dose level into liver, lung, kidney, heart muscle, but not brain. It has been shown to have a potent, broad spectrum of activity in vitro2).
We compared the effectiveness of L-640,876 with that of mecillinam, cefoxitin and cefotaxime against experimental septicemia in mice and investigated the influence of inoculum size and 6-lactamase production of the infecting organism on the outcome of chemotherapy.
Materials and Methods

Antibiotics
Laboratory powders of L-640,876 and cefoxitin sodium (Merck & Co., Inc.), cefotaxime (Hoechst AG, Frankfurt) and mecillinam (Leo Pharmaceutical Products, Ballerup) were used in these studies. All possessed a potency of greater than 900 lig/mg. Animals Female CD1 mice were purchased from Charles River Breeding Laboratories, Wilmington, MA. They were housed in a temperature-controlled environment and fed Purina Formulab Chow # 5008 and provided tap water ad libitum.
Efficacy Studies Mice weighing, on the average, 1922 g were injected intraperitoneally (i.p.) with 0.5 ml of an appropriate dilution of the pathogen in brain heart infusion broth (Difco) (for Streptococcus pyogenes MB 2874 and Klebsiella pneumoniae MB 4005) or in 5 % hog gastric mucin (Wilson, Division of Inolex Corp., Park Forest South, IL). All infected, untreated mice died within 48 hours.
Drugs were given as aqueous solutions by the subcutaneous (s.c.) route in divided doses at 0 and 6 hours after infection. Each therapy group consisted of at least five mice; four fourfold dilutions of each antibiotic were tested. All animals were observed for 7 days after infection and the number of survivors on that day was used to calculate the median effective dose (ED50) by the method of KNUDSEN and CURTIS3).
Pharmacokinetics
Groups of five 20 g mice were given a single s.c. dose of 10, 20 or 50 mg/kg of L-640,876 and 0.5 ml water by gavage to stimulate urine flow. The five mice were then placed in a metabolism cage designed to collect urine free from fecal contamination.
At a specified time, a group was bled by heart puncture, the pooled blood was allowed to clot and the serum was removed after centrifugation. At the same time, urine from that group was collected and the volume measured. All serum and urine samples were stored at -20°C until bioassayed.
In other groups of mice given 50 mg/kg of L-640,876 s.c., livers, left kidneys, lungs, hearts and brains in addition to blood, were removed at 1, 2 and 4 hours after dosing. The tissues were homogenized in SORENSEN's buffer (pH 7) and adjusted to 200 mg tissue/ml. These samples also were stored at -20°C until bioassayed.
Agar-Dilution Susceptibility Tests
The minimum inhibitory concentration (MIC) was determined in an agar-dilution assay using nutrient agar or nutrient agar supplemented with 10% horse serum (for Streptococcus pyogenes MB 2874). Overnight cultures and appropriate dilutions thereof were deposited with the aid of an automated multipronged inoculator onto the surface of the agar which contained doubling-dilutions of antibiotic. The final inoculum for each of the organisms used later in the mouse protection tests was 104 CFU/spot. For the 3 organisms used in studies of the in vivo inoculum effect, the CFU/spot corresponded to the CFU in the challenge dose. The test plates were incubated at 35°C for 18 hours. The MIC was defined as the lowest concentration of antibiotic that suppressed visible growth.
Microbiological Assays
The antibiotic content of serum, urine and tissues was determined by standard disc diffusion procedures using nutrient agar supplemented with 0.2% yeast extract. Escherichia coli MB 2891 (for serum and urine) and E. coli MB 4269 (for tissues) served as the assay organisms. Serum samples were diluted in normal mouse serum, urine in SORENSEN's buffer (pH 6) and tissues in SORENSEN's buffer (pH 7). Potencies were calculated from the appropriate standard curves, in some cases with the aid of a computer program.
Cultures All bacterial cultures were of human or animal origin and were selected because of their virulence for mice. They were maintained in the lyophilized state before use. Identifying numbers are those of the Merck stock culture collection.
Results and Discussion
Chemotherapeutic Trials
The therapeutic effectiveness of L-640,876 was demonstrated against experimental systemic infections in mice. Results of these studies in comparison with mecillinam and cefotaxime are shown in Table 1 . The ED50 values are from single trials in which all three antibiotics were tested simultaneously. They are representative of values obtained from other mouse protection tests in which only I or 2 of the antibiotics was evaluated.
The potent, broad spectrum activity of L-640,876 seen in vitro2) was also evident in vivo when the antibiotic was given by the s.c. route to mice infected with any of a number of Gram-positive or Gramnegative pathogens. In general, the MIC was a good predictor of in vivo efficacy.
L-640,876 was more effective than mecillinam and comparable to cefotaxime in protecting mice against infections with staphylococci and streptococci.
Against the Gram-negative pathogens, L-640,876 was as effective as mecillinam against Enterobacter cloacae, Salmonella schottmuelleri and the 3 strains of E. coli tested. It was considerably more active than mecillinam against Proteus morganii, Proteus mirabilis, Proteus vulgaris and Klebsiella aInfection was established by the intraperitoneal injection of an appropriate dilution of the pathogen in brain heart infusion broth (Streptococcus pyogenes, Klebsiella pneunioniae) or in 5 % hog gastric mucin; colony-forming units (CFU) were calculated using standard plate counting techniques and the number of median lethal doses (LD50) by the method of KNUDSEN and CURTIS3). b Minimum inhibitory concentration (MIC) in itg/ml at 104 CFU applied to the agar surface with a multipoint inoculator .
c Median effective dose (ED50) in mg/kg/dose; drugs were administered by the subcutaneous route in divided doses at 0 and 6 hours after infection. a MIC in jig/ml; determined in an agar-dilution assay using nutrient agar and a multipronged inoculator. b ED bo in mg/kg; antibiotics were given s.c. at 0 and 6 hours after infection. pneumoniae. This latter infection was refractory to treatment with mecillinam although the organism was susceptible to the antibiotic in vitro.
In general, L-640,876 was as efficacious as cefotaxime in protecting mice against most infections caused by Gram-negative organisms. There were two notable exceptions. The Enterobacter infection was controlled by L-640,876 at lower doses than those required for cefotaxime, as might be expected from the respective MICs. On the other hand, Klebsiella pneumoniae, which was equally susceptible to both antibiotics in vitro, was less well controlled by L-640,876 than by cefotaxime (15-fold more active) in vivo.
The Klebsiella and Enterobacter were the only organisms for which the excellent in vitro activity of L-640,876 was not translated into highly effective therapy in vivo in single digit or lower values.
In Vivo Inoculum Effect KOUPAL et a1.2) showed that increasing the inoculum size of certain Gram-negative bacteria increased the MIC of L-640,876 and that this increase was associated with stability of the cephem to the 3-lactamase elaborated by the organism or the presence of certain salts in the culture medium. To determine whether the ED50 would also be influenced by increases in inoculum size, mouse protection tests were performed in which the challenge doses were increased in 100-fold increments. Antibiotics were administered by s.c. injection immediately after infection and again 6 hours later. The pathogens studied were E. co/i MB 2891 and Proteus morganii MB 2833, known ;-3-lactamase producers, and Proteus mirabilis MB 3125, a strain that does not produce 3-lactamase. Results of these tests are shown in Table 2 .
In the study with E. coli MB 2891, a strain that was highly susceptible to L-640,876 in vitro, a ten thousand-fold increase in the challenge dose increased the ED50 only 68-fold from 0.06 mg/kg to 4.08 mg/ kg. The increase in inoculum size had little effect on the MIC of mecillinam but raised the ED50 more than 600-fold from 0.03 mg/kg to 20 mg/kg. In contrast, the MICs and ED50s for cefotaxime were adversely affected by increasing inoculum for this strain of E. coli. Although this organism is considered to be resistant to cefoxitin, increases in inoculum size had little or no effect on the MIC or ED50 of this antibiotic.
In studies with Proteus morganii MB 2833 and Proteus mirabilis MB 3125, large increases in MICs of L-640,876 were seen with 100-fold increases in inoculum size, and significantly greater amounts of the antibiotic were required to protect mice against bacteremia induced by both of these pathogens as the challenge dose was increased. Mecillinam was considerably less active against the smaller inoculum than was L-640,876 and ineffective when tested against the larger inoculum both in vitro and in vivo.
The MICs and ED50s of cefotaxime and cefoxitin were only slightly affected by increases in inoculum sizes of these pathogens.
Since significant shifts in MIC as a function of inoculum size for both L-640,876 and mecillinam are known to be due to 3-lactamase production, conductivity effected by certain salts including sodium chloride, or both2), the reason(s) for the higher dose required to protect infected animals under these conditions must be approached with caution. Suffice it to say that, in the case of the Proteus strain, the MIC is a good predictor of ED50. The lack of correlation of MIC and ED50 for the E. coli strain, especially in view of the high resistance of L-640,876 to the,3-lactamase produced by the organism, at present cannot be explained.
Pharmacokinetics
In groups of mice given a single s.c. dose of 10, 20 or 50 mg/kg of L-640,876, peak serum concentra-tions, half-lifes (tz) and areas under the serum concentration vs. time curves (AUC) increased as the dose increased (Table 3) . Serum peaks were observed at 15 minutes after each dose and ranged from a high of 72.5 iig/ml to a low of 12.4 jig/ml. The tz values were 36, 27 and 19 minutes and AUC, 45.8, 16.5 and 10.1 jig-hours/ml following the 50, 20 and 10 mg/kg doses, respectively.
Concentrations of antibiotic in all urine samples exceeded 100 jig/ml at 1, 2 and 4 hours after dosing and total recovery of antibiotic activity increased as the dose increased. The cumulative percent of dose excreted in urine during the four hour interval after dosing varied inversely with the dose but remained fairly constant over the range tested, 41.8 % after the 50 mg/kg dose to 48.7 % after the 10 mg/kg dose. The antibiotic was not absorbed when given to mice by gavage.
In other groups of mice given 50 mg/kg of L-640,876 s.c., the antibiotic content in liver, kidney, lung, heart and brain, in addition to serum, was determined at 1, 2 and 4 hours after dosing. The results are shown in Table 4 .
Serum values were comparable to those obtained from mice used in the study reported in Table 3 .
Among the solid tissues, liver was found to contain the highest amount of antibiotic activity (Table 4) , approximately twice that in serum at 1 and 2 hours after dosing. Antibiotic activity in the kidney approached that in the serum at 1 hour after the 50 mg/kg dose (10.85 pg/g compared to 13.0 pg/ml) but declined rapidly thereafter. Lung and heart contained 3.6 and 1.7 jig/g, respectively, at 1 hour after dosing and little or no activity at the other times sampled. No activity was detected in brain tissue (sensitivity of bioassay was 0.02 pg/ml) indicating no passage of the antibiotic across the normal meninges of young adult mice under the conditions of this experiment. AUC-Area under the serum concentration vs. time curve. A computer program was used to calculate these parameters. b Sensitivity of assay=0 .5 pg/ml; assay organism was E. coli MB 2891. Sensitivity of assay=0.02 jig/ml; assay organism was E. coil MB 4269. Potencies were determined with the aid of a computer-assisted image analyzer.
